Thyme Care Secures $97M Series D to Expand AI-Driven Oncology Solutions

Thyme Care has announced a $97 million Series D funding round, backed by strategic investors such as CVS Health Ventures and JPMorgan Chase, announced in a press release. This funding brings Thyme Care's total capital raised to $275 million.

The company, which manages over $5 billion in oncology spending and serves 8 million people nationwide, aims to dismantle barriers in cancer care through an AI orchestration layer. This technology reduces cognitive overload on care teams and accelerates stakeholder integration, providing timely and personalized support to patients.

With new contracts in Medicare, commercial, and employer sectors, Thyme Care is positioned to expand its national scale and improve outcomes in oncology care. The funding will support the company's mission to build an integrated oncology infrastructure focused on value, accountability, and enhancing patient experiences.